Thus, these data support a model of tumor recurrence or progression despite BCG therapy, highlighting the PD-1/PD-L1 and HLA-E/NKG2A axes as immune checkpoints that may be exploited in this context. This evidence concerns the gene HLA-E and neoplasm.